Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02390908 · ClinicalTrials.gov registry record · NA

Improving HIV and Alcohol-Related Outcomes Among HIV+ Persons in Clinic Settings

A NA study of HIV and Medication Adherence, sponsored by Hunter College of City University of New York.

Completed
Registry status
NA
Development phase
174
Enrollment target
1
Study location

NCT02390908: Completed NA study of HIV and Medication Adherence, sponsored by Hunter College of City University of New York.

NCT02390908 is a NA study of HIV and Medication Adherence that has completed, run by Hunter College of City University of New York. The registered enrollment target is 174 participants, below the 439-participant average among 303 other HIV trials with a reported enrollment target (60% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02390908, a NA study of HIV and Medication Adherence, has completed, sponsored by Hunter College of City University of New York.

COMPLETED
Registry status
NA
Development phase
174 participants
Enrollment target
1
Study location

Study Summary

Alcohol use is increasingly recognized as a key factor in morbidity and mortality among HIV-positive individuals and represents an important public health concern, given its associations with medication non-adherence, increases in viral load, poor immunologic outcomes (lower cluster of differentiation 4, or CD4, counts), drug resistance, lower health care utilization, comorbidities (HIV/viral hepatitis coinfection), and poor health outcomes overall. Adherence to HIV medications has a double public health benefit, both in terms of slowing disease progression and improving health outcomes among HIV-positive individuals and in helping to curb the sexual transmission of HIV. The objective of this study is to implement a multisite comparative effectiveness trial in real-world clinical settings with three intensities of treatment to test the clinical and cost effectiveness of an efficacious, theory-based behavioral intervention (PLUS) in improving adherence to antiretroviral therapy (ART) and alcohol-related outcomes among HIV-positive individuals who drink alcohol at harmful or hazardous levels. The study is being conducted in collaboration between the Center for HIV Educational Studies and Training (CHEST) at Hunter College at the City University of New York (CUNY) and the Spencer Cox Center for Health at the Institute for Advanced Medicine, Mount Sinai Health System.

Primary Outcome

Standard of care HIV-1 viral load results were run using local laboratories and results were abstracted from EMR data, indicating the participant's most recent viral load result. Each viral load result indicates the number of HIV copies in a milliliter (copies/mL), and raw values were log-transformed to deal with non-normal distribution. Minimum and maximum log-viral load values in the current sample were 1.28 and 6.07, respectively.

Interventions

  • BEHAVIORAL Immediate PLUS intervention
  • BEHAVIORAL Wait-list PLUS intervention

Study Locations (1)

New York

  • Center for HIV/AIDS Educational Studies and Training of Hunter College, CUNY - New York

Trial Details

FieldValue
Enrollment Target 174 participants
Start Date 2013-08-01
Est. Completion 2018-05-08
Phase NA

What the finished NCT02390908 record still lists

NCT02390908 is an interventional study that assigns participants to a tested intervention. The registered 174 participants enrollment target is mid-sized for trials with a published cap, below the 439-participant average among 303 other HIV trials with a reported enrollment target (60% lower).

The record links to 3 conditions, with HIV appearing as the primary indexed condition, and to 2 interventions - of which Immediate PLUS intervention is the first listed.

NCT02390908 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT02390908 about?

NCT02390908 is a clinical study titled "Improving HIV and Alcohol-Related Outcomes Among HIV+ Persons in Clinic Settings". Alcohol use is increasingly recognized as a key factor in morbidity and mortality among HIV-positive individuals and represents an important public health concern, given its associations with medication non-adherence, increases in viral load, poor immunologic outcomes (lower cluster of differentiati...

What is the current status of trial NCT02390908?

This trial is currently completed. It is a NA study. The enrollment target is 174 participants. The study started on 2013-08-01. Estimated completion is 2018-05-08.

What conditions does trial NCT02390908 study?

This clinical trial studies the following conditions: HIV, Medication Adherence, Alcohol Use.

What interventions are being tested in trial NCT02390908?

The interventions under investigation include: Immediate PLUS intervention (BEHAVIORAL), Wait-list PLUS intervention (BEHAVIORAL).

Who is sponsoring clinical trial NCT02390908?

This trial is sponsored by Hunter College of City University of New York, which has 29 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02390908 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for HIV

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02390908's enrollment target sits among peer trials

174 125th of 303 higher than 179 of 303 other HIV trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other HIV trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01000259 · 174 participants

    Study of Tumor Tissue Samples From Patients Who Have Undergone Surgery for Advanced Stage III or Stage IV Ovarian Epithelial Cancer

  • NCT04729114 · 174 participants · Phase 1

    A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer

  • NCT04884035 · 174 participants · Phase 1

    Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma

  • NCT05075980 · 174 participants · Phase 2

    Intensity Modulated Proton or X-Ray Therapy After Surgery for Treatment of Head and Neck Cancer, the HEADLIGHT Study

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT02390908, the US trial registry maintained by the National Library of Medicine. NCT02390908 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.